ARES CAPITAL CORP - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Ares Capital Corporation (ARCC) on February 5, 2025. The filing reports the entry into new material definitive agreements regarding equity distribution and the termination of prior agreements with the same counterparties.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. It is a disclosure of a capital raising mechanism rather than a financial results report.
Material Changes
- New Equity Distribution Agreements: On February 5, 2025, the Company entered into separate agreements with Truist Securities, Jefferies LLC, Mizuho Securities USA LLC, RBC Capital Markets, LLC, and Regions Securities LLC (collectively, the "Sales Agents").
- Offering Capacity: The Company may issue and sell shares of common stock with an aggregate offering price of up to $1,500,000,000.
- Sales Method: Shares may be sold in negotiated transactions or "at the market" transactions (Rule 415(a)(4)) on the NASDAQ Global Select Market or through market makers.
- Compensation: Sales Agents will receive a commission of up to 1.5% of the gross sales price of shares sold.
- Termination of Prior Agreements: The Company terminated previous equity distribution agreements dated July 30, 2024, with the same five Sales Agents, which have been superseded by the new agreements.
Guidance, Outlook, and Risks
The Company has no obligation to sell any shares under the new agreements and may suspend the offering at any time. Actual sales will depend on market conditions, the trading price of the Company's common stock, and management's determination of capital needs. The filing includes standard legal disclaimers that the report does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful.
Investor Verification Checklist
- Verify the full text of the Equity Distribution Agreements filed as Exhibits 10.1 through 10.5 for specific terms and conditions.
- Review the Registration Statement on Form N-2 (File No. 333-279023) and the Prospectus Supplement dated February 5, 2025, for detailed offering terms.
- Monitor future filings to determine if and when the Company elects to sell shares under this $1.5 billion program.
- Assess the impact of potential dilution should the Company utilize the full offering capacity.